Log In
BCIQ
Print this Print this
 

ARB-1467 (formerly TKM-HBV)

  Manage Alerts
Collapse Summary General Information
Company Arbutus Biopharma Corp.
DescriptionLipid nanoparticle (LNP) formulated RNAi therapy that targets 3 highly conserved regions of the HBV viral genome
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II
Standard IndicationHepatitis B virus (HBV)
Indication DetailsTreat chronic HBV infection
Regulatory Designation
PartnerArcturus Therapeutics Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$437.8M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/04/2015

$437.8M

0

0

Get a free BioCentury trial today